<DOC>
	<DOCNO>NCT01960842</DOCNO>
	<brief_summary>The primary objective study measure efficacy ABT-SLV187 subject advance Parkinson 's disease .</brief_summary>
	<brief_title>A Study Assess Efficacy , Safety Tolerability ABT-SLV187 Monotherapy Subjects With Advanced Parkinson 's Disease ( PD ) Persistent Motor Complications , Despite Optimized Treatment With Available Anti-Parkinsonian Medications</brief_title>
	<detailed_description>The study compose screen period follow 2 sequential on-treatment period , follow : - Screening Period ( 28 day ) : determination eligibility discontinuation antiparkinsonian disease medication levodopa-carbidopa immediate release ( LC-oral ) prior nasojejunal ( N-J ) tube placement . - N-J Test Period ( 2 14 day ) : first hospitalization period , Baseline assessment , placement N-J tube , optimization levodopa-carbidopa intestinal gel ( LCIG ) treatment via N-J tube infusion pump ( participant hospitalize N-J tube placement hospitalization require entire duration LCIG treatment optimization ) . - PEG-J Period ( 12 week ) : second hospitalization period ; placement PEG-J tube ; optimization LCIG treatment .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Antiparkinson Agents</mesh_term>
	<criteria>1 . Diagnosis idiopathic Parkinson 's disease accord United Kingdom Parkinson 's Disease Society ( UKPDS ) Brain Bank Criteria . 2 . Subjects 4 5 modify Hohn Yahr ( H &amp; Y ) classification disease severity `` Off '' state determine UPDRS Part V Screening Visit 1 . 3 . The subject 's advanced Parkinson 's disease must levodoparesponsive judged Investigator . 4 . Subjects optimal treatment available Parkinson 's disease medication define local standard care , base upon judgment Investigator , symptom judge inadequately control optimize treatment . Optimized treatment define maximum therapeutic effect obtain available antiparkinsonian pharmacological therapy improvement expect regardless additional manipulation levodopa and/or anti parkinsonian medication ; base Investigator 's best clinical judgment . 5 . Presence recognizable `` Off '' `` On '' state ( motor fluctuation ) confirm UPDRS Part III ( `` On '' `` Off '' state ) , Parkinson 's Disease DiaryÂ© must observe confirmed Screening Visit 1 . 6 . Subjects must experience minimum 3 hour per day `` Off '' time , estimate Investigator support UPDRS Screening Visit 1 Parkinson 's Disease Diaries baseline . The `` Off '' time must occur continuous 16hour interval , include portion day subject awake majority time ( e.g. , 5 AM 9 PM , 7 AM 11 PM ) . 1 . Parkinson 's disease diagnosis unclear suspicion parkinsonian syndrome exists , secondary Parkinsonism ( cause drug , toxin , infectious agent , vascular disease , trauma , brain neoplasm ) , Parkinson'splus syndrome ( e.g. , multiple system atrophy , progressive supranuclear palsy ) neurodegenerative disease might mimic symptom Parkinson 's disease . 2 . Subjects undergone neurosurgery treatment Parkinson 's disease . 3 . Current primary psychiatric diagnosis acute psychotic disorder uncontrolled primary psychiatric diagnosis , ( e.g. , bipolar disorder major depressive disorder per Diagnostic Statistical Manual Mental Disorders 4th edition , Text Revision ( DSMIVTR ) criterion . 4 . Alzheimer 's disease ; significant cognitive impairment dementia ( define MiniMental State Examination ( MMSE ) total score &lt; 24 ) . 5 . Subject significant current suicidal ideation within previous year evidence answer `` yes '' question 4 5 suicidal ideation portion ColumbiaSuicide Severity Rating Scale ( CSSRS ) complete Screening history suicide attempt . 6 . A low B12 level lownormal B12 level ( le 300 pg/mL ) elevate methylmalonic acid ( MMA ) . Note : Abnormal Vitamin B12 questionable clinical significance ( i.e. , indeterminate low normal result ) prior Screening Visit 2 require appropriate interpretation conjunction MMA homocysteine laboratory value prior proceed study .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>levodopa</keyword>
	<keyword>Advanced Parkinson 's Disease</keyword>
	<keyword>carbidopa</keyword>
	<keyword>levodopa-carbidopa intestinal gel</keyword>
	<keyword>Safety Efficacy</keyword>
</DOC>